EVENITY
Biological
Amgen Inc.
Total Payments
$31.8M
Transactions
382,707
Doctors
71,446
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $8.3M | 72,371 | 28,972 |
| 2023 | $5.9M | 60,097 | 25,014 |
| 2022 | $4.8M | 64,990 | 25,563 |
| 2021 | $4.2M | 67,009 | 25,201 |
| 2020 | $3.0M | 51,279 | 19,525 |
| 2019 | $5.6M | 66,950 | 25,732 |
| 2018 | $246.88 | 11 | 11 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.1M | 239 | 44.4% |
| Food and Beverage | $7.6M | 372,421 | 23.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7.6M | 4,573 | 23.8% |
| Travel and Lodging | $1.3M | 4,639 | 4.0% |
| Consulting Fee | $1.2M | 405 | 3.6% |
| Space rental or facility fees (teaching hospital only) | $56,798 | 40 | 0.2% |
| Education | $5,074 | 390 | 0.0% |
Payments by Type
General
$17.6M
382,468 transactions
Research
$14.1M
239 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Innovative Approach to Geriatric Osteoporosis | Amgen Inc. | $3.3M | 0 |
| Clinical Characteristics, including History of MI and Stroke, among US Post-Menopausal Women Initiating Treatment with Romosozumab and Other Anti-Osteoporosis Therapies | Amgen Inc. | $2.5M | 0 |
| Effects of Romosozumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women with Anorexia Nervosa: A Pilot Study | Amgen Inc. | $2.4M | 0 |
| Romosozumab for Premenopausal Idiopathic Osteoporosis | Amgen Inc. | $2.1M | 0 |
| FDA PMC: Multi year OR of Romosozumab patients relative to CV risk factors in other OP patients | Amgen Inc. | $1.3M | 0 |
| Ph3 PMO Fracture Study ALN SupVert | Amgen Inc. | $816,023 | 4 |
| PMO Self Administration Study ++ | Amgen Inc. | $639,592 | 0 |
| Effects of Romosozumab on Bone Health in Women with Spinal Cord Injury and Osteoporosis | Amgen Inc. | $481,014 | 0 |
| P3 Safety & Efficacy OI Pediatric | Amgen Inc. | $202,993 | 0 |
| FDA PMC: Multi-year OR of Romosozumab patients relative to CV risk factors in other OP patients | Amgen Inc. | $156,873 | 0 |
| Ph3 PMO Fracture Study Placebo | Amgen Inc. | $120,536 | 2 |
| PMO Self Administration Study | Amgen Inc. | $58,543 | 0 |
| P1 dose esc pediatric OI | Amgen Inc. | $55,698 | 0 |
| An Open-Label Phase 2 Study of Romosozumab to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty | Amgen Inc. | $41,028 | 0 |
| Dose Ranging Study | Amgen Inc. | $25,863 | 0 |
| Testing generalizability of Crystal Bone, an AI/ML osteoporotic fracture risk prediction algorithm, using real-world evidence from three US health systems | Amgen Inc. | $15,965 | 4 |
| GalgoDXA 3D imaging Hip cortico and trabecular bone structure | Amgen Inc. | $6,528 | 0 |
| Clinical Impact of Acute Symptomatic Vertebral Fractures in the United States | Amgen Inc. | $4,850 | 3 |
| Medical management patterns following non-traumatic fracture in US post-menopausal women | Amgen Inc. | $3,935 | 1 |
| Ph2b Hip Femoral Neck Fracture Healing | Amgen Inc. | $3,347 | 1 |
Top Doctors Receiving Payments for EVENITY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Burlington, MA | $14.3M | 246 |
| , M.D | Endocrinology, Diabetes & Metabolism | Portland, OR | $689,755 | 684 |
| , M.D | Specialist | West Haverstraw, NY | $620,276 | 436 |
| , MD | Rheumatology | Bannockburn, IL | $321,259 | 607 |
| , DO | Foot and Ankle Surgery | Camarillo, CA | $284,985 | 432 |
| Andrea Singer | Internal Medicine | Washington, DC | $256,711 | 302 |
| , M.D | Rheumatology | Phoenix, AZ | $248,795 | 385 |
| , M.D | Geriatric Medicine | Laguna Hills, CA | $224,006 | 529 |
| , M.D.,F.R.C.P.C | Endocrinology, Diabetes & Metabolism | Beaumont, TX | $222,265 | 346 |
| , M.D | Internal Medicine | San Francisco, CA | $198,898 | 228 |
| , MD | Rheumatology | Atlanta, GA | $198,837 | 316 |
| , MSN, FNP | Family | Mount Vernon, IL | $160,066 | 355 |
| , M.D | Rheumatology | Babylon, NY | $144,687 | 246 |
| , M.D | Rheumatology | Myrtle Beach, SC | $132,241 | 242 |
| , MD | Rheumatology | Shreveport, LA | $123,558 | 181 |
| , M.D | Rheumatology | Lafayette, LA | $115,046 | 179 |
| , M.D | Rheumatology | Boca Raton, FL | $114,272 | 198 |
| , M.D | Rheumatology | Zephyrhills, FL | $111,804 | 221 |
| , M.D | Internal Medicine | Chicago, IL | $110,322 | 161 |
| , M.D | Endocrinology, Diabetes & Metabolism | New York, NY | $110,258 | 169 |
| , M.D | Internal Medicine | Cincinnati, OH | $109,496 | 171 |
| , MD | Rheumatology | Cleveland, OH | $106,753 | 105 |
| , M.D | Rheumatology | Boynton Beach, FL | $104,348 | 180 |
| , MD | Endocrinology, Diabetes & Metabolism | Sarasota, FL | $104,262 | 126 |
| , M.D | Endocrinology, Diabetes & Metabolism | Spokane Valley, WA | $102,890 | 165 |
Ad
Manufacturing Companies
- Amgen Inc. $31.8M
Product Information
- Type Biological
- Total Payments $31.8M
- Total Doctors 71,446
- Transactions 382,707
About EVENITY
EVENITY is a biological associated with $31.8M in payments to 71,446 healthcare providers, recorded across 382,707 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2018 to 2024. In 2024, $8.3M was paid across 72,371 transactions to 28,972 doctors.
The most common payment nature for EVENITY is "Unspecified" ($14.1M, 44.4% of total).
EVENITY is associated with 20 research studies, including "Innovative Approach to Geriatric Osteoporosis" ($3.3M).